Exagen Inc. XGN Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.
The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Exagen Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price?
- Exagen Inc. (XGN) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price of $5.91 in Q1 2026.
- How has Exagen Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price changed year-over-year?
- Exagen Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price decreased by 20.4% year-over-year, from $7.42 to $5.91.
- What is the long-term trend for Exagen Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price?
- Over 5 years (2020 to 2025), Exagen Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price has grown at a -10.3% compound annual growth rate (CAGR), from $11.81 to $6.86.